阿尔茨海默病患者的运动加行为管理:一个随机对照试验
Linda Teri1, Laura E Gibbons, Susan M McCurry
1Department of Psychosocial and Community Health, University of Washington, Seattle 98195, USA. lteri@u.washington.edu
JAMA
|October 16, 2003
概括
家庭运动计划与护理人员培训相结合,改善了阿尔茨海默病患者的身体功能,减少了阿尔茨海默病患者的抑郁症. 这次干预也显示了两年来机构化减少的趋势.
科学领域:
- 老年学是一门学科.
- 神经学 神经学
- 康复医学 康复医学 康复医学
背景情况:
- 阿尔茨海默病 (AD) 与脆弱性和行为障碍有关.
- 护理人员的支持对于管理AD症状和患者福祉至关重要.
研究的目的:
- 为了评估一个家庭运动计划与AD患者的护理人员培训相结合.
- 评估该计划对功能依赖和制度化率的影响.
主要方法:
- 一项随机对照试验,涉及153名社区居住的AD患者及其照顾者.
- 参与者被分配到阿尔茨海默病减少残疾 (RDAD) 计划或常规医疗护理 (RMC) 中.
- 该RDAD计划包括3个月的家庭炼和行为管理培训.
主要成果:
- 与RMC相比,RDAD参与者炼更多,限制活动日减少.
- 在RDAD组的身体角色功能和抑郁症得分中观察到显著的改善.
- 在2年后,RDAD患者保持了更好的身体功能,并显示出减少住院治疗的趋势.
结论:
- 将运动与护理人员培训相结合,可以改善阿兹海默症患者的身体健康和情绪.
- 这种综合方法为管理阿尔茨海默病症状和改善患者治疗结果提供了一个有希望的策略.
相关概念视频
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Behavior Modification
Behavioral approaches have often been criticized for ignoring mental processes and focusing solely on observable behavior. However, these approaches provide an optimistic perspective for individuals seeking to change their behaviors. Rather than concentrating on intrinsic personality traits, behavioral approaches suggest that even longstanding habits can be modified by changing the reward contingencies that maintain them.
A real-world application of operant conditioning principles is applied...
A real-world application of operant conditioning principles is applied...


